secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2026-06-30T12:30:20+00:00
Accession:  0001493152-26-031204
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics regains Nasdaq bid price compliance; will effect 1-for-6 reverse split
--------------------------------------------------------------------------------

- Nasdaq Panel confirmed compliance with Bid Price Rule; mandatory monitoring through June 17, 2027.
- Company to effect 1-for-6 reverse stock split on June 30, 2026 to maintain compliance.
- If non-compliant during monitoring, no additional cure period; may face delisting.
- Company now compliant with all Nasdaq continued listing rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/0001493152-26-031204-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000149315226031204/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-031204

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer